Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response

Author(s):
Keystone, E.; Heijde, D. van der; Smolen, J.; Weinblatt, M.; Kvien, T.; Strand, V.; Ansari, Z.; Goel, N.; Combe, B.
Published
2010
Publication type
Other
Date issued
2010-06-30
Language
English
hdl
1887/117782